Co-expression of vascular and lymphatic endothelial cell markers on early endothelial cells present in aspirated coronary thrombi from patients with ST-elevation myocardial infarction

Exp Mol Pathol. 2016 Feb;100(1):31-8. doi: 10.1016/j.yexmp.2015.11.028. Epub 2015 Dec 2.

Abstract

Introduction: Angiogenesis is the growth of both new vascular and lymphatic blood vessels from the existing vasculature. During this process, blood endothelial cells (BECs) and lymphatic endothelial cells (LECs) express specific markers, which help their discrimination and easier identification. Since the coronary thrombi material aspirated from patients with ST-elevation myocardial infarction (STEMI) proved as good angiogenesis model, we investigated the expression of CD34 and CD31 as BECs markers, and D2-40, LYVE-1 and VEGFR3 as LEC markers in this material.

Materials and methods: Aspirated thrombi were stained immunohistochemically for CD34, CD31, D2-40, LYVE-1 and VEGFR3. Organizational patterns of immunopositive cells were graded as single cells, clusters or microvessels. Double immunofluorescence for CD31, D2-40, LYVE-1 and VEGRF3 was done. Thrombi were also graded as fresh (<1day old), lytic (1-5days old) and organized (>5days old).

Results: Serial sections of aspirated thrombi showed concordant BEC and LEC markers immunopositivity. Double immunoflorescence proved co-expression of CD31 and LEC markers on the same cells. Cells expressing LEC markers organized in clusters and microvessels were mainly present in lytic and organized thrombi.

Conclusion: Co-expression of BEC and LEC markers on the same non-tumorous cell during thrombus neovascularization indicates existing in vivo plasticity of endothelial cells under non-tumorous pathological conditions. It also points that CD34 and CD31 on one hand, and D2-40, LYVE-1 and VEGFR3 immunostaining on the other hand, cannot solely be a reliable indicators whether vessel is lymphatic or not.

Keywords: CD31; CD34; Coronary thrombus aspiration; Coronary thrombus neovascularization; D2-40; LYVE-1; ST-elevation myocardial infarction; VEGFR3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD34 / metabolism*
  • Biomarkers / analysis
  • Endothelial Cells / metabolism*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / blood
  • Myocardial Infarction / metabolism*
  • Myocardial Infarction / pathology
  • Neovascularization, Pathologic / metabolism
  • Platelet Endothelial Cell Adhesion Molecule-1 / metabolism*
  • Thrombosis / metabolism
  • Vascular Endothelial Growth Factor Receptor-3 / metabolism*
  • Vesicular Transport Proteins / metabolism*

Substances

  • Antigens, CD34
  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • LYVE1 protein, human
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Vesicular Transport Proteins
  • FLT4 protein, human
  • Vascular Endothelial Growth Factor Receptor-3